Howard Amital

Efficacy and safety of tofacitinib monotherapy, tofacitinib with methotrexate, and adalimumab with methotrexate in patients with rheumatoid arthritis (ORAL Strategy): a phase 3b/4, double-blind, head-to-head, randomised controlled trial

Roy Fleischmann, Eduardo Mysler, Stephen Hall et al. · The Lancet · 2017 · 496 citations

Medicine, Pharmacology, Pharmacotherapy +12

Immune-Mediated Disease Flares or New-Onset Disease in 27 Subjects Following mRNA/DNA SARS-CoV-2 Vaccination

‬‬‬‬Abdulla Watad, Gabriele De Marco, Hussein Mahajna et al. · Vaccines · 2021 · 372 citations · Full text

Veterinary Medicine, Immunology, Infectious Diseases +17

Adding tocilizumab or switching to tocilizumab monotherapy in methotrexate inadequate responders: 24-week symptomatic and structural results of a 2-year randomised controlled strategy trial in rheumatoid arthritis (ACT-RAY)

Maxime Dougados, K. Kissel, Tom Sheeran et al. · Annals of the Rheumatic Diseases · 2012 · 287 citations · Full text

Medicine, Pharmacology, Pharmacotherapy +15

Serum concentrations of 25-OH vitamin D in patients with systemic lupus erythematosus (SLE) are inversely related to disease activity: is it time to routinely supplement patients with SLE with vitamin D?

Howard Amital, Zoltán Szekanecz, Gabriella Szűcs et al. · Annals of the Rheumatic Diseases · 2010 · 285 citations · Full text

Medicine, Immunology, Autoimmunity +16

Novel Biomarkers in Autoimmune Diseases

Hedi Orbach, Gisele Zandman‐Goddard, Howard Amital et al. · Annals of the New York Academy of Sciences · 2007 · 232 citations · Full text

Life Sciences, Endocrinology, Immunology +12